Dr. Golan on the Phase III POLO Trial in BRCA-Mutant Pancreatic Cancer
Talia Golan, MD, head of Sheba Pancreatic Cancer Center, discusses the results of the phase III POLO trial, which evaluated maintenance olaparib compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.
Talia Golan, MD, head of Sheba Pancreatic Cancer Center, discusses the results of the phase III POLO trial, which evaluated maintenance olaparib (Lynparza) compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.
These are remarkable results, says Golan, as this is the first biomarker-driven phase III trial that is positive in pancreatic cancer, demonstrating a move forward for the field, Golan says. This trial comprised patients with BRCA1/2 mutations with stable disease or had a partial response to first-line chemotherapy. Then, in the maintenance setting, patients received either olaparib or placebo.
The study met its primary endpoint of progression-free survival (PFS); the median PFS was 7.4 months with olaparib versus 3.8 months with placebo, and the duration of response was longer than 2 years, Golan explains.
